Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00706264 |
Recruitment Status :
Completed
First Posted : June 27, 2008
Results First Posted : March 17, 2021
Last Update Posted : March 17, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Preterm Birth | Device: Silicon ring (Arabin Pessary) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 385 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Randomized Controlled Trial: Prevention of Preterm Birth Using Cervical Pessary in Pregnant Women With Short Cervix (PECEP) |
Study Start Date : | June 2007 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |
Arm | Intervention/treatment |
---|---|
No Intervention: 1
Expectant management
|
|
Experimental: 2
Placement of arabin pessary since 23 weeks until 37 weeks
|
Device: Silicon ring (Arabin Pessary)
Placement of a silicon pessary in the vagina, around the cervix.
Other Name: Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003 |
- Spontaneous Delivery Before 34 Completed Weeks [ Time Frame: Between 24 and 34 weeks ]Number of spontaneous preterm births before 34 weeks occurred in each group.
- Birthweight Less Than 1500 g [ Time Frame: Time of delivery ]Number of newborns whose birthweight is less than 1500 grams
- Birthweight Less Than 2500 g [ Time Frame: Time of delivery ]Number of newborns whose birthweight is less than 2500 grams
- Intrauterine Fetal Demise [ Time Frame: Pregnancy ]The number of fetal deaths in the pessary group was compared to those in the no pessary group
- Neonatal Death [ Time Frame: Between birth and 28 days of age ]The number of neonatal deaths in the pessary group was compared to those in the no pessary group
- Intraventricular Haemorrhage [ Time Frame: Between birth and 28 days of age ]The number of neonatal intraventricular haemorrhage in the pessary group was compared to those in the no pessary group
- Respiratory Distress Syndrome [ Time Frame: Between birth and 28 days of age ]The number of neonatal Respiratory distress syndrome in the pessary group was compared to those in the no pessary group
- Retinopathy of Prematurity [ Time Frame: Between birth and 28 days of age ]The number of neonatal retinopathy in the pessary group was compared to those in the no pessary group
- Necrotising Enterocolitis [ Time Frame: Between birth and 28 days of age ]The number of neonatal necrotising enterocolitis in the pessary group was compared to those in the no pessary group
- Treatment for Sepsis [ Time Frame: Between birth and 28 days of age ]The number of neonatal cases of treatment needed for sepsis in the pessary group was compared to those in the no pessary group
- Composite Adverse Outcomes [ Time Frame: Between birth and 28 days of age ]The number of neonatal cases with composite adverse outcomes in the pessary group was compared to those in the no pessary group
- Spontaneous Delivery Before 28 Completed Weeks [ Time Frame: Between 24 and 28 weeks ]Number of preterm births before 28 weeks occurred in each group.
- Any Delivery Before 34 Completed Weeks [ Time Frame: Between 24 and 34 weeks ]Number of all preterm births before 34 weeks occurred in each group.
- Spontaneous Delivery Before 37 Completed Weeks [ Time Frame: Between 24 and 37 weeks ]Number of preterm births before 37 weeks occurred in each group.
- Gestational Age at Delivery [ Time Frame: At time of birth ]Number of weeks of gestation completed by time of delivery
- Use of Tocolysis [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants required use of tocolytic medication
- Use of Antenatal Steroids [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants that received betamethasone to reduce morbidity of expected preterm delivery
- Chorioamnionitis [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants that showed intrauterine infection diagnosed by maternal tachycardia, fever, uterine tenderness, purulent or abnormal cervical discharge, fetal tachycardia.
- Vaginal Bleeding [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants who experienced bleeding from lower genital tract during antepartum period
- Preterm Premature Rupture of Membranes [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants who experienced rupture of membranes as diagnosed by speculum exam showing pooling, ferning, positive nitrazine test, positive amnisure test.
- Cesarean Delivery [ Time Frame: At time of delivery ]Number of participants that underwent cesarean delivery
- Vaginal Discharge [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants who experienced an increased vaginal discharge.
- Pessary Repositioning Without Removal [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants who required pessary repositioning without removal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).
- Pessary Withdrawal [ Time Frame: participants will be followed for the duration of pregnancy, up to nine months ]Number of participants who experience pessary withdrawal. This outcome measure only applied to the Experimental (Pessary Arm) and no data were collected from participants in the No Intervention _(No Pessary Arm).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Singleton pregnancy
- Minimal age of 18 years
Exclusion Criteria:
- Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
- SROM at the time of randomization
- Cervical cerclage in situ
- Active vaginal bleeding
- Previous cone biopsy or cerclage
- Major uterine structural anomalies
- Placenta previa

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00706264
Spain | |
Hospital Materno-Infantil de Canarias | |
Las Palmas de Gran Canaria, Gran Canaria, Spain, 35016 | |
Hospital Son Llàtzer | |
Palma de Mallorca, Mallorca, Spain, 07198 | |
Hospital de Reus | |
Reus, Tarragona, Spain | |
Hospital Vall d´Hebron | |
Barcelona, Spain, 08035 | |
Institut Universitary Dexeus | |
Barcelona, Spain | |
Hospital de Fuenlabrada | |
Madrid, Spain |
Study Director: | ELENA CARRERAS, PhD | Maternal-Infantil Vall d´Hebron Hospital |
Responsible Party: | Maria Goya, MD, PhD, PhD, Maternal-Infantil Vall d´Hebron Hospital |
ClinicalTrials.gov Identifier: | NCT00706264 |
Other Study ID Numbers: |
PECEP-TRIAL |
First Posted: | June 27, 2008 Key Record Dates |
Results First Posted: | March 17, 2021 |
Last Update Posted: | March 17, 2021 |
Last Verified: | March 2021 |
Short cervix preterm birth arabin pessary |
Premature Birth Obstetric Labor, Premature Obstetric Labor Complications Pregnancy Complications |
Silicon Trace Elements Micronutrients Physiological Effects of Drugs |